Clinical features and long‐term outcomes of patients with type 2 autoimmune pancreatitis
United European Gastroenterology Journal · 2024
DOI: 10.1002/ueg2.12504 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift United European Gastroenterology Journal, 2024. Verfasst von Nicolò de Pretis und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, University of Verona, Verona, Italy. Hauptthemen laut MEDLINE: Autoimmune Pancreatitis, Pancreatitis, Autoimmune Diseases. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Objectives
Type 2 is a rare form of autoimmune pancreatitis (AIP). Despite being considered a benign disease, only few studies with limited sample size and short follow‐up have been published on type 2 AIP. The aim of this observational study was to evaluate long‐term outcomes, such as the risk of relapse, pancreatic insufficiency and cancer in a large type 2 AIP cohort with long follow‐up.
Methods
Patients with definitive or probable diagnosis of type 2 AIP by International Consensus Diagnostic Criteria (ICDC) present in our prospectively maintained database since 1995 at 31.12.2021 were identified. All patients were clinically evaluated during the year 2022. Clinical, radiological, serological, and pathological data were evaluated.
Results
Eighty‐eight out of 420 patients present in the database (21%) were diagnosed with type 2 AIP (mean age 33.5 ± 13.5 years). According to the ICDC, 21 patients (23.8%) had a definitive and 67 (76.2%) a probable diagnosis of type 2 AIP. The mean follow‐up was 9.2 ± 7.1 years (range 1–27 years). No differences were observed when comparing patients with definitive and probable type 2 AIP diagnosis. Concomitant IBD was reported in 77 patients (87.5%). The probability of disease relapse was lower in patients treated with steroids versus surgery (at 5 years 13% vs. 33%; p = 0.038) but this difference was not statistically significant at multivariable analysis. The risk of endocrine or severe exocrine insufficiency was low (5% and 25%). Four extra‐pancreatic malignancies (5%) were diagnosed, none pancreatic. One patient died in a car accident.
Conclusions
Type 2 AIP has benign long‐term clinical outcomes. Mortality and cancer rates are low and no specific follow‐up is needed after radiological remission.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Medicine, University of Verona, Verona, Italy.
- Department of Diagnostics and Public Health, University of Verona, Verona, Italy.
ORCID-Profile: Nicolò de Pretis, Federico Caldart, Maria Cristina Conti Bellocchi, Stefano Francesco Crinò, Luca Frulloni
Zitieren
APA
de Pretis, N., Carlin, M., Calderini, E., Caldart, F., Conti Bellocchi, M. C., Amodio, A., De Marchi, G., Campagnola, P., Crinò, S. F., Bernardoni, L., Gabbrielli, A., Martinelli, L., & Frulloni, L. (2024). Clinical features and long‐term outcomes of patients with type 2 autoimmune pancreatitis. United European Gastroenterology Journal. https://doi.org/10.1002/ueg2.12504
Vancouver
de Pretis N, Carlin M, Calderini E, Caldart F, Conti Bellocchi MC, Amodio A, et al. Clinical features and long‐term outcomes of patients with type 2 autoimmune pancreatitis. United European Gastroenterology Journal. 2024. doi:10.1002/ueg2.12504
BibTeX
@article{dePretis2024,
author = {de Pretis, Nicolò and Carlin, Michele and Calderini, Emilia and Caldart, Federico and Conti Bellocchi, Maria Cristina and Amodio, Antonio and De Marchi, Giulia and Campagnola, Pietro and Crinò, Stefano Francesco and Bernardoni, Laura and Gabbrielli, Armando and Martinelli, Luigi and Frulloni, Luca},
title = {Clinical features and long‐term outcomes of patients with type 2 autoimmune pancreatitis},
journal = {United European Gastroenterology Journal},
year = {2024},
doi = {10.1002/ueg2.12504}
}
EUVIMED